secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0001193125-22-298441
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz acquires exclusive zanidatamab rights from Zymeworks for $50M upfront
--------------------------------------------------------------------------

- Upfront $50M non-refundable cash payment; potential $325M payment after HERIZON-BTC-01 top-line data.
- Regulatory milestones up to $525M; commercial milestones up to $862.5M.
- Tiered royalties of 10%-20% on annual net sales in the Territory.
- Exclusive rights in U.S., Europe, Japan; Asia/Pacific territories excluded per prior BeiGene license.
- Agreement effective Nov 29, 2022 following HSR clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312522298441/0001193125-22-298441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312522298441/d428448d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-298441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer